Comparative Pharmacology
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus KALLIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus KALLIGA.
CYPROHEPTADINE HYDROCHLORIDE vs KALLIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
None Documented
None Documented
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category A/B
Category C
Antihistamine
Antihistamine